[{"AccountsReceivableNetCurrent_0_Q2_USD":4545000000.0,"ProceedsFromSaleAndMaturityOfMarketableSecurities_2_Q2_USD":45000000.0,"SeniorNotes_0_Q2_USD":25846000000.0,"GainLossRelatedToLitigationSettlement_2_Q2_USD":12000000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1_Q2_USD":144000000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2_Q2_USD":-416000000.0,"OtherLiabilitiesCurrent_0_Q2_USD":995000000.0,"PaymentsForProceedsFromOtherInvestingActivities_2_Q2_USD":-10000000.0,"LineOfCreditFacilityMaximumBorrowingCapacity_0_Q2_USD":2300000000.0,"AccountsPayableTradeCurrent_0_Q2_USD":1606000000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q2_USD":544000000.0,"LongTermNotesAndLoans_0_Q2_USD":24616000000.0,"OtherLiabilitiesNoncurrent_0_Q2_USD":2411000000.0,"ProceedsFromPaymentsForOtherFinancingActivities_2_Q2_USD":-3000000.0,"ImpairmentOfIntangibleAssetsExcludingGoodwill_2_Q2_USD":768000000.0,"ImpairmentOfIntangibleAssetsExcludingGoodwill_1_Q2_USD":120000000.0,"DebtCurrent_0_Q2_USD":1649000000.0,"AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_0_Q2_USD":69000000.0,"ImpairmentOfLongLivedAssetsHeldForUse_1_Q2_USD":277000000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q2_USD":2402000000.0,"IncomeLossFromEquityMethodInvestments_2_Q2_USD":0.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1_Q2_USD":-51000000.0,"DeferredIncomeTaxAssetsNet_0_Q2_USD":483000000.0,"LongTermDebtCurrent_0_Q2_USD":1136000000.0,"RepaymentsOfLongTermDebt_2_Q2_USD":700000000.0,"SellingAndMarketingExpense_1_Q2_USD":597000000.0,"SellingAndMarketingExpense_2_Q2_USD":1210000000.0,"EarningsPerShareDiluted_1_Q2_USD":0.13,"OtherAssetsCurrent_0_Q2_USD":448000000.0,"EarningsPerShareDiluted_2_Q2_USD":0.19,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q2_USD":0.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2_Q2_USD":0.0,"TreasuryStockShares_0_Q2_shares":107000000.0,"TreasuryStockValue_0_Q2_USD":4128000000.0,"ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1_Q2_USD":204000000.0,"ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2_Q2_USD":-301000000.0,"IncomeLossFromEquityMethodInvestments_1_Q2_USD":0.0,"InventoryFinishedGoodsNetOfReserves_0_Q2_USD":2281000000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2_Q2_USD":-84000000.0,"ImpairmentOfLongLivedAssetsHeldForUse_2_Q2_USD":352000000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2_Q2_USD":62000000.0,"OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax_1_Q2_USD":0.0,"OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax_2_Q2_USD":0.0,"OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax_1_Q2_USD":-7000000.0,"OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax_2_Q2_USD":-37000000.0,"OtherInventoryInTransit_0_Q2_USD":179000000.0,"OtherOperatingActivitiesCashFlowStatement_2_Q2_USD":17000000.0,"ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1_Q2_USD":225000000.0,"OperatingLeaseRightOfUseAsset_0_Q2_USD":489000000.0,"ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_2_Q2_USD":446000000.0,"RestructuringCharges_1_Q2_USD":33000000.0,"RestructuringReserve_0_Q2_USD":137000000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":8227000000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":3870000000.0,"TangibleAssetImpairmentCharges_1_Q2_USD":277000000.0,"TangibleAssetImpairmentCharges_2_Q2_USD":352000000.0,"ValuationAllowancesAndReservesBalance_0_Q2_USD":5275000000.0,"RestructuringCharges_2_Q2_USD":73000000.0,"IncreaseDecreaseInOperatingCapital_2_Q2_USD":1002000000.0,"OperatingLeaseLiabilityNoncurrent_0_Q2_USD":414000000.0,"InventoryWorkInProcessNetOfReserves_0_Q2_USD":618000000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q2_USD":32000000.0,"AssetsFairValueAdjustment_2_Q2_USD":-272000000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":427000000.0,"DebtInstrumentFairValue_0_Q2_USD":24726000000.0,"DeferredFinanceCostsNoncurrentNet_0_Q2_USD":94000000.0,"DeferredTaxAndOtherLiabilitiesNoncurrent_0_Q2_USD":975000000.0,"DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent_0_Q2_USD":11000000.0,"LossContingencyAccrualAtCarryingValue_0_Q2_USD":1588000000.0,"DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_0_Q2_USD":154000000.0,"EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_Q2_USD":-13000000.0,"FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_2_Q2_USD":1000000.0,"FairValueNetAssetLiability_0_Q2_USD":1935000000.0,"GoodwillForeignCurrencyTranslationGainLoss_2_Q2_USD":219000000.0,"GoodwillImpairedAccumulatedImpairmentLoss_0_Q2_USD":21000000000.0,"ImpairmentOfLongLivedAssetsToBeDisposedOf_2_Q2_USD":261000000.0,"InventoryRawMaterialsNetOfReserves_0_Q2_USD":1282000000.0,"DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_0_Q2_USD":176000000.0,"ValuationAllowancesAndReservesDeductions_2_Q2_USD":8466000000.0,"OtherComprehensiveIncomeLossNetOfTax_2_Q2_USD":-379000000.0,"ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_2_Q2_USD":-119000000.0,"LiabilitiesNoncurrent_0_Q2_USD":28417000000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":-703000000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":565000000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":578000000.0,"NetIncomeLoss_1_Q2_USD":140000000.0,"NetIncomeLoss_2_Q2_USD":209000000.0,"OtherOperatingIncomeExpenseNet_1_Q2_USD":9000000.0,"LiabilitiesCurrent_0_Q2_USD":11751000000.0,"OtherOperatingIncomeExpenseNet_2_Q2_USD":22000000.0,"ProfitLoss_1_Q2_USD":53000000.0,"ProfitLoss_2_Q2_USD":78000000.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":6122000000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-6747000000.0,"StockholdersEquity_0_Q2_USD":13852000000.0,"AdjustmentForAmortization_1_Q2_USD":249000000.0,"AdjustmentForAmortization_2_Q2_USD":507000000.0,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":259000000.0,"CommonStockParOrStatedValuePerShare_0_Q2_CHF":0.1,"LiabilitiesAndStockholdersEquity_0_Q2_USD":54991000000.0,"InventoryNet_0_Q2_USD":4361000000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":-2703000000.0,"AdditionalPaidInCapital_0_Q2_USD":27374000000.0,"AssetImpairmentCharges_2_Q2_USD":1120000000.0,"Assets_0_Q2_USD":54991000000.0,"AssetsCurrent_0_Q2_USD":12781000000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":2402000000.0,"CommonStockSharesIssued_0_Q2_shares":1202000000.0,"Liabilities_0_Q2_USD":40167000000.0,"CommonStockValue_0_Q2_USD":57000000.0,"EarningsPerShareBasicAndDiluted_2_Q2_USD":0.19,"GeneralAndAdministrativeExpense_1_Q2_USD":264000000.0,"GeneralAndAdministrativeExpense_2_Q2_USD":567000000.0,"GrossProfit_1_Q2_USD":1763000000.0,"GrossProfit_2_Q2_USD":3826000000.0,"IncomeTaxExpenseBenefit_1_Q2_USD":-104000000.0,"IncomeTaxExpenseBenefit_2_Q2_USD":-163000000.0,"EarningsPerShareBasicAndDiluted_1_Q2_USD":0.13,"OtherComprehensiveIncomeLossNetOfTax_1_Q2_USD":151000000.0,"CommonStockSharesAuthorized_0_Q2_shares":2495000000.0,"FiniteLivedIntangibleAssetsAccumulatedAmortization_0_Q2_USD":11396000000.0,"FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0_Q2_USD":471000000.0,"Goodwill_0_Q2_USD":24616000000.0,"LitigationSettlementExpense_1_Q2_USD":13000000.0,"MinorityInterest_0_Q2_USD":972000000.0,"NetIncomeLossAttributableToNoncontrollingInterest_1_Q2_USD":-87000000.0,"NetIncomeLossAttributableToNoncontrollingInterest_2_Q2_USD":-131000000.0,"NonoperatingIncomeExpense_1_Q2_USD":-223000000.0,"EarningsPerShareBasic_2_Q2_USD":0.19,"NonoperatingIncomeExpense_2_Q2_USD":-448000000.0,"StockIssuedDuringPeriodValueNewIssues_1_Q2_USD":null,"StockIssuedDuringPeriodValueNewIssues_2_Q2_USD":null,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":1096000000.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":1095000000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":289000000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":-182000000.0,"ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_1_Q2_USD":-85000000.0,"OtherAssetsNoncurrent_0_Q2_USD":560000000.0,"DepreciationAndAmortization_2_Q2_USD":781000000.0,"EarningsPerShareBasic_1_Q2_USD":0.13,"CostOfGoodsAndServicesSold_1_Q2_USD":2107000000.0,"OperatingIncomeLoss_1_Q2_USD":173000000.0,"OperatingIncomeLoss_2_Q2_USD":364000000.0,"ShareBasedCompensation_2_Q2_USD":62000000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q2_shares":1100000000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_2_Q2_shares":1098000000.0,"AllowanceForDoubtfulAccountsReceivableCurrent_0_Q2_USD":129000000.0,"AmortizationOfIntangibleAssets_1_Q2_USD":249000000.0,"CostOfGoodsAndServicesSold_2_Q2_USD":4402000000.0,"AmortizationOfIntangibleAssets_2_Q2_USD":507000000.0,"FiniteLivedIntangibleAssetsGross_0_Q2_USD":21336000000.0,"FiniteLivedIntangibleAssetsNet_0_Q2_USD":9940000000.0,"PrepaidExpenseCurrent_0_Q2_USD":956000000.0,"StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0_Q2_USD":14824000000.0,"BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_1_Q2_USD":76000000.0,"BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_2_Q2_USD":83000000.0,"BusinessCombinationContingentConsiderationLiability_0_Q2_USD":484000000.0,"DerivativeLossOnDerivative_2_Q2_USD":493000000.0,"EntityCommonStockSharesOutstanding_0_Q2_shares":1095776777.0,"Ticker":"TEVA","CIK":"818686","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","OfficialName":"Teva Pharmaceutical Industries Limited American Depositary Shares","form":"10-Q","period":"20200630","fy":"2020.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"11303387401.0","Country":"Israel","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NYSE","SP500":"nan","filed":"20200805"}]